HEART

• Rita Case, president and CEO of Rick Case Automotive Group, the nation’s largest female owned and operated automotive dealer group in America, received the 55th Annual TIME Dealer of the Year Award, one of the automotive industry’s most prestigious and highest honors for a dealer.
• Rita is only the fifth woman to be named TIME Dealer of the Year.
• TIME Dealer of the Year is the highest honor and most prestigious recognition an auto dealer can receive from the auto industry, and I am humbled and grateful for this award,” Rita said, as she received the award during the 107th Annual NADA Show in Las Vegas.
• In 2023, the Community Foundation of Broward recognized Rita as a Community Builder and celebrated the establishment of the Rita & Rick Case Family Fund during a special ceremony.

• WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2023 and provided key business updates.
• “During the third quarter, we initiated our plan to move the istaroxime program in cardiogenic shock to Phase 3 readiness by advancing two clinical trials.
• Research and development expenses were $2.1 million for the third quarter of 2023, compared to $1.5 million for the third quarter of 2022.
• General and administrative expenses for the third quarter of 2023 were $2.6 million, compared to $2.7 million for the third quarter of 2022.

• Ever since, #MeToo has been shorthand for people’s experiences with sexual harassment and assault, from film sets and office buildings to college campuses and religious communities.
• Many articles about #MeToo and religion focus on large churches, such as the Southern Baptist Convention – spaces that are mostly white and Christian.
• These women face added challenges when they break the silence around sexual misconduct and abuse of power, as I document in my book “#UsToo.” Many Jewish and Muslim women of color navigate three kinds of oppression simultaneously: sexism, racism and antisemitism or Islamophobia.

’Dirty laundry’

• This problem is not exclusive to Jewish or Muslim communities but rather a general problem for all subcultures.
• Publicly airing communal “dirty laundry” is seen as precarious, both for the individual and for the ethnoreligious group.
• Jewish and Muslim women in the United States are diverse, from different levels of religious observance to ethnic identity.

Risks of silence and interdependence

• The insularity, sense of connection and interdependence within some minority communities can be conducive to abuses of power.
• Word spread quickly in the Jewish community, and other women came out of the woodwork about his behavior.
• Sacred Spaces, incorporated in 2016, is another organization that brings Jewish values to its work addressing and preventing abuse.

Walking a tightrope

• Nevertheless, some Muslim women affected by sexual misconduct have been working for years to bring it out of the communal closet and into the public eye.
• Many of the women I interviewed live on a tightrope: calling out the patriarchy and sexual misconduct they experienced, while defending their community against anti-Muslim stereotypes.
• HEART, a sexual health and reproductive justice organization founded in 2009, offers education and resources to discuss sexual relationships and violence.
• Despite this progress, many Jewish and Muslim women are still apprehensive about reporting coreligionists, as are women in larger Christian communities.

• The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.
• The newly issued patent follows the Company’s announcement in April 2023 that the European Patent Office granted Patent No.
• 3599243, which also provides patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
• Istaroxime and these follow-on SERCA2a Activators look to deliver on the potential of SERCA2a activation in heart failure.